

27 August 2024

**Belluscura plc**  
**("Belluscura" or the "Company")**

**Result of General Meeting**

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that at the Annual General Meeting held earlier today, all resolutions proposed were duly approved by shareholders:

	Total votes for	% of shares voted	Total votes against	% of shares voted	Total votes	Votes withheld
<b>Ordinary resolutions</b>						
Resolution 1: To receive and adopt the report of the directors and the audited accounts of the Company for the period ended 31 December 2023	91,444,802	99.94	55,722	0.06	91,500,524	-
Resolution 2: To re-elect Simon Neicheril as a director of the Company	91,426,718	99.94	54,753	0.06	91,481,471	19,053
Resolution 3: To re-elect Robert Fary as a director of the Company	91,426,718	99.94	54,753	0.06	91,481,471	19,053
Resolution 4: To re-elect Paul Tuson as a director of the Company	91,426,574	99.94	54,897	0.06	91,481,471	19,053
Resolution 5: To re-appoint Gerald Edelman LLP as auditor to the Company	91,456,503	99.95	43,877	0.05	91,500,380	144
Resolution 6: To authorise the directors to determine the remuneration of the auditors	91,442,594	99.96	38,877	0.04	91,481,471	19,053
Resolution 7: To grant the directors authority to allot shares pursuant to Section 551 of the Companies Act 2006 and grant rights to subscribe for, or convert any security into, shares	91,439,344	99.93	61,180	0.07	91,500,524	-
<b>Special resolutions</b>						
Resolution 8: To dis-apply pre-emption rights pursuant to Section 570 of the Companies Act 2006	86,818,255	94.90	4,663,216	5.10	91,481,471	19,053
Resolution 9: To authorise the directors to make market purchases	86,896,258	94.97	4,604,266	5.03	91,500,524	-

**For further information please contact:**

Tel: +44 (0)20 3128 8100

**Belluscura plc**  
Adam Reynolds, Chairman  
Robert Rauker, Chief Executive Officer  
Simon Neicheril, Chief Financial Officer

**SPARK Advisory Partners Limited**  
**(Nominated Adviser)**  
Neil Baldwin / Jade Bayat

Tel: +44 (0)20 3368 3550

**Dowgate Capital Limited**  
**(Broker)**  
James Serjeant / Russell Cook

Tel: +44 (0)20 3903 7715

**MHP Group**  
**(Financial PR & Investor Relations)**  
Katie Hunt / Matthew Taylor

Tel: +44 (0)20 3128 8100  
belluscura@mhpgroup.com

**About Belluscura plc (<https://belluscura.com/>)**

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGMEADPXAFKLEFA